Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

330 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI.
de Langen AJ, van den Boogaart V, Lubberink M, Backes WH, Marcus JT, van Tinteren H, Pruim J, Brans B, Leffers P, Dingemans AM, Smit EF, Groen HJ, Hoekstra OS. de Langen AJ, et al. Among authors: dingemans am. J Nucl Med. 2011 Jan;52(1):48-55. doi: 10.2967/jnumed.110.078261. Epub 2010 Dec 13. J Nucl Med. 2011. PMID: 21149474 Free article. Clinical Trial.
Inter-reader reproducibility of dynamic contrast-enhanced magnetic resonance imaging in patients with non-small cell lung cancer treated with bevacizumab and erlotinib.
van den Boogaart VE, de Lussanet QG, Houben RM, de Ruysscher D, Groen HJ, Marcus JT, Smit EF, Dingemans AM, Backes WH. van den Boogaart VE, et al. Among authors: dingemans am. Lung Cancer. 2016 Mar;93:20-7. doi: 10.1016/j.lungcan.2015.12.009. Epub 2015 Dec 30. Lung Cancer. 2016. PMID: 26898610 Clinical Trial.
Pemetrexed plus carboplatin versus pemetrexed in pretreated patients with advanced non-squamous non-small-cell lung cancer: treating the right patients based on individualized treatment effect prediction.
van Kruijsdijk RC, Visseren FL, Boni L, Groen HJ, Dingemans AM, Aerts JG, van der Graaf Y, Ardizzoni A, Smit EF. van Kruijsdijk RC, et al. Among authors: dingemans am. Ann Oncol. 2016 Jul;27(7):1280-6. doi: 10.1093/annonc/mdw154. Epub 2016 Apr 6. Ann Oncol. 2016. PMID: 27052652 Free article. Clinical Trial.
Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AM, Joerger M, Schellens JH, Vincent A, van Zandwijk N, Groen HJ. Smit EF, et al. Among authors: dingemans am. J Clin Oncol. 2009 Apr 20;27(12):2038-45. doi: 10.1200/JCO.2008.19.1650. Epub 2009 Mar 23. J Clin Oncol. 2009. PMID: 19307503 Clinical Trial.
A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.
Lind JS, Dingemans AM, Groen HJ, Thunnissen FB, Bekers O, Heideman DA, Honeywell RJ, Giovannetti E, Peters GJ, Postmus PE, van Suylen RJ, Smit EF. Lind JS, et al. Among authors: dingemans am. Clin Cancer Res. 2010 Jun 1;16(11):3078-87. doi: 10.1158/1078-0432.CCR-09-3033. Epub 2010 Apr 15. Clin Cancer Res. 2010. PMID: 20395213 Free article. Clinical Trial.
Low molecular weight heparins in the treatment of lung cancer.
Mellema WW, Smit EF, Dingemans AM. Mellema WW, et al. Among authors: dingemans am. Expert Opin Investig Drugs. 2011 Nov;20(11):1517-22. doi: 10.1517/13543784.2011.625008. Epub 2011 Oct 7. Expert Opin Investig Drugs. 2011. PMID: 21978327 Review.
330 results